Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gegen Qinlian Tablets with tislelizumab and chemotherapy for advanced lung squamous cell carcinoma
ChiCTR2100051747Phase 4Not yet recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Gegenqinlian Decoction and tislelizumab in Pulmonary squamous cell carcinoma, sponsored by China-Japan Friendship Hospital. Primary endpoints: Objective response rate and Disease control rate. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
Gegenqinlian Decoctiontislelizumab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR2100051747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051747.